FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 124 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations... September 20, 2022 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 FDA Proposes Changes to Mammography Standards to Inform Women About Breast... March 28, 2019 Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib... August 27, 2026 Load more HOT NEWS New option to treat advanced oesophageal cancer approved for NHS in... News digest – targeted radiation beam, precision medicine and our early... Moving target – retrotransposable elements and cancer iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with...
